Professor Matt Stevenson

All publications

Journal articles

• Dark P, Hossain A, McAuley DF, Brealey D, Carlson G, Clayton JC, Felton TW, Ghuman BK, Gordon AC, Hellyer TP , Lone NI et al (2025) Biomarker-guided antibiotic duration for hospitalized patients with suspected sepsis: the ADAPT-sepsis randomized clinical trial. Journal of the American Medical Association (JAMA), 333(8). View this article in WRRO
• Bullement A, Edmondson-Jones M, Guyot P, Welton NJ, Baio G, Stevenson M & Latimer NR (2024) MPES-R: multi-parameter evidence synthesis in R for survival extrapolation—a tutorial. PharmacoEconomics. View this article in WRRO
• Abhishek A, Grainge M, Card T, Williams HC, Taal MW, Aithal GP, Fox CP, Mallen CD, Stevenson MD, Nakafero G & Riley R (2024) Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation. RMD Open, 10(1), e003980-e003980.
• Dangouloff T, Thokala P, Stevenson MD, Deconinck N, D'Amico A, Daron A, Delstanche S, Servais L & Hiligsmann M (2024) Cost-effectiveness of spinal muscular atrophy newborn screening based on real-world data in Belgium. Neuromuscular Disorders, 34, 61-67.
• Abhishek A, Stevenson MD, Nakafero G, Grainge MJ, Evans I, Alabas O, Card T, Taal MW, Aithal GP, Fox CP , Mallen CD et al (2023) Discontinuation of anti-TNF-alpha treatment due to blood test abnormalities and cost-effectiveness of alternate blood monitoring strategies. British Journal of Dermatology, ljad430.
• Nakafero G, Card T, Grainge MJ, Williams HC, Taal MW, Aithal GP, Fox CP, Mallen CD, van der Windt DA, Stevenson MD , Riley RD et al (2023) Risk-stratified monitoring for thiopurine toxicity in immune-mediated inflammatory diseases: prognostic model development, validation, and, health economic evaluation. eClinicalMedicine, 64, 102213-102213.
• Metry A, Pandor A, Ren S, Shippam A, Clowes M, Dark P, McMullan R & Stevenson M (2023) Cost-effectiveness of therapeutics for COVID-19 patients: a rapid review and economic analysis. Health Technology Assessment, 27(14). View this article in WRRO
• Nakafero G, Grainge MJ, Williams HC, Card T, Taal MW, Aithal GP, Fox CP, Mallen CD, van der Windt DA, Stevenson MD , Riley RD et al (2023) Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK.. BMJ, 381, e074678.
• Bullement A, Critchlow S, Stevenson MD, Baio G & Latimer N (2022) A REVIEW OF EXTERNAL EVIDENCE USED TO SUPPORT SURVIVAL EXTRAPOLATION IN ASSESSMENTS OF CANCER DRUGS BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE). VALUE IN HEALTH, 25(12), S340-S340.
• Mandrik O, Fotheringham J, Ren S, Tice JA, Chapman RH, Stevenson MD, Pearson SD, Herron-Smith S, Agboola F & Thokala P (2022) The cost-effectiveness of belimumab and voclosporin for patients with Lupus Nephritis in the United States. Clinical Journal of the American Society of Nephrology, 17(3), 385-394. View this article in WRRO
• Graham CN, Watson C, Barlev A, Stevenson M & Dharnidharka V (2022) Mean lifetime survival estimates following solid organ transplantation in the US and UK. Journal of Medical Economics, 1-28.
• Murphy P, Glynn D, Dias S, Hodgson R, Claxton L, Beresford L, Cooper K, Tappenden P, Ennis K, Grosso A , Wright K et al (2021) Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.. Health technology assessment (Winchester, England), 25(76), 1-228.
• Kearns B, Stevenson MD, Triantafyllopoulos K & Manca A (2021) Comparing current and emerging practice models for the extrapolation of survival data : a simulation study and case-study. BMC Medical Research Methodology, 21(1). View this article in WRRO
• Thomas KH, Dalili MN, López‐López JA, Keeney E, Phillippo DM, Munafò MR, Stevenson M, Caldwell DM & Welton NJ (2021) Comparative clinical effectiveness and safety of tobacco cessation pharmacotherapies and electronic cigarettes : a systematic review and network meta‐analysis of randomized controlled trials. Addiction.
• Thomas KH, Dalili MN, López-López JA, Keeney E, Phillippo D, Munafò MR, Stevenson M, Caldwell DM & Welton NJ (2021) Smoking cessation medicines and e-cigarettes : a systematic review, network meta-analysis and cost-effectiveness analysis. Health Technology Assessment, 25(59), 1-224.
• Kainz B, Heinrich MP, Makropoulos A, Oppenheimer J, Mandegaran R, Sankar S, Deane C, Mischkewitz S, Al-Noor F, Rawdin AC , Ruttloff A et al (2021) Non-invasive diagnosis of deep vein thrombosis from ultrasound imaging with machine learning. npj Digital Medicine, 4. View this article in WRRO
• Kearns B, Stevenson M, Triantafyllopoulos K & Manca A (2021) The extrapolation performance of survival models for data with a cure fraction: a simulation study. Value in Health. View this article in WRRO
• Stevenson M, Metry A & Messenger M (2021) Modelling of hypothetical SARS-CoV-2 point of care tests for routine testing in residential care homes: rapid cost-effectiveness analysis. Health Technology Assessment, 25(39).
• Keeney E, Welton NJ, Stevenson M, Dalili MN, López-López JA, Caldwell DM, Phillippo DM, Munafò MR & Thomas KH (2021) Cost-effectiveness analysis of smoking cessation interventions in the United Kingdom accounting for major neuropsychiatric adverse events. Value in Health.
• Li N, Sawyer EK, Maruszczyk K, Guzauskas G, Slomka MT, Burke T, Martin AP, O’Hara J, Stevenson M & Recht M (2021) Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model. Journal of Medical Economics, 24(1), 363-372.
• Stevenson M, Metry A & Messenger M (2021) Modelling of hypothetical SARS-CoV-2 point-of-care tests on admission to hospital from A&E : rapid cost-effectiveness analysis. Health Technology Assessment, 25(21), 1-68. View this article in WRRO
• Floreskul V, Juma FZ, Daniel AB, Zamir I, Rawdin A, Stevenson M, Mughal Z & Padidela R (2020) Cost-effectiveness of vitamin D supplementation in pregnant woman and young children in preventing rickets: a modeling study. Frontiers in Public Health, 8.
• Stevenson M, Uttley L, Oakley JE, Carroll C, Chick SE & Wong R (2020) Interventions to reduce the risk of surgically transmitted Creutzfeldt–Jakob disease: a cost-effective modelling review. Health Technology Assessment, 24(11), 1-150. View this article in WRRO
• Uttley L, Carroll C, Wong R, Hilton DA & Stevenson M (2020) Creutzfeldt-Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation. The Lancet Infectious Diseases, 20(1), e2-e10. View this article in WRRO
• Thokala P, Stevenson M, Kumar VM, Ren S, Ellis AG & Chapman RH (2020) Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US. Cost Effectiveness and Resource Allocation, 18(1).
• Pearson SD, Thokala P, Stevenson M & Rind D (2019) The effectiveness and value of treatments for spinal muscular atrophy. Journal of Managed Care & Specialty Pharmacy, 25(12), 1300-1306. View this article in WRRO
• Kearns B, Stevenson M, Triantafyllopoulos K & Manca A (2019) Generalized linear models for flexible parametric modeling of the hazard function. Medical Decision Making, 39(7), 867-878. View this article in WRRO
• Youn J-H, Stevenson MD, Thokala P, Payne K & Goddard M (2019) Modeling the economic impact of interventions for older populations with multimorbidity : a method of linking multiple single-disease models. Medical Decision Making. View this article in WRRO
• Simpson EL, Ren S, Hock ES, Stevens JW, Binard A, Pers Y-M, Archer R, Paisley S, Stevenson MD, Herpin C & Ghabri S (2019) Rheumatoid arthritis treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis.. International Journal of Technology Assessment in Health Care. View this article in WRRO
• Goodacre S, Horspool K, Nelson-Piercy C, Knight M, Shephard N, Lecky F, Thomas S, Hunt BJ & Fuller G (2019) The DiPEP study: an observational study of the diagnostic accuracy of clinical assessment, D-dimer and chest x-ray for suspected pulmonary embolism in pregnancy and postpartum. BJOG: An International Journal of Obstetrics & Gynaecology, 126(3), 383-392. View this article in WRRO
• Archer R, Hock E, Hamilton J, Stevens J, Essat M, Poku E, Clowes M, Pandor A & Stevenson M (2018) Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews.. Health Technology Assessment, 22(66), 1-294. View this article in WRRO
• Doherty M, Jenkins W, Richardson H, Sarmanova A, Abhishek A, Ashton D, Barclay C, Doherty S, Duley L, Hatton R , Rees F et al (2018) Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. The Lancet, 392(10156), 1403-1412. View this article in WRRO
• Alemao E, Al MJ, Boonen AA, Stevenson MD, Verstappen SMM, Michaud K, Weinblatt ME & Rutten-van Mölken MPMH (2018) Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. PLoS ONE, 13(10), e0205013-e0205013. View this article in WRRO
• Ghabri S, Stevenson M, Möller J & Caro JJ (2018) Trusting the Results of Model-Based Economic Analyses: Is there a Pragmatic Validation Solution?. Pharmacoeconomics. View this article in WRRO
• Hatswell AJ, Bullement A, Briggs A, Paulden M & Stevenson MD (2018) Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models. PharmacoEconomics. View this article in WRRO
• Ren S, Bermejo I, Simpson E, Wong R, Scott D, Young A & Stevenson M (2018) Baricitinib for previously treated moderate or severe rheumatoid arthritis: an evidence review group perspective of a NICE single technology appraisal . PharmacoEconomics, 36, 769-778. View this article in WRRO
• Bermejo I, Ren S, Simpson E, Clowes M, Scott DL, Young A & Stevenson M (2018) Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 36(12), 1427-1437. View this article in WRRO
• Dickson R, Boland A, Duarte R, Kotas E, Woolacott N, Hodgson R, Riemsma R, Grimm S, Ramaekers B, Joore M , Büyükkaramikli N et al (2018) EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties. Applied Health Economics and Health Policy. View this article in WRRO
• Simpson EL, Hock E, Stevenson M, Wong R, Dracup N, Wailoo A, Conaghan PG, Estrach C, Edwards CJ & Wakefield RJ (2018) What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis. Health Technology Assessment, 22(20). View this article in WRRO
• Uttley L, Bermejo I, Ren S, Martyn-St James M, Wong R, Scott DL, Young A & Stevenson M (2018) Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 36(9), 1063-1072. View this article in WRRO
• Stevenson M, Pandor A, Hamilton J, Stevens J, Rowntree C, Martyn-St James M, Rawdin A & Wong R (2018) Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 36(7), 759-768. View this article in WRRO
• Pandor A, Stevenson M, Stevens J, James MM-S, Hamilton J, Byrne J, Rudin C, Rawdin A & Wong R (2018) Ponatinib for Treating Chronic Myeloid Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 36(8), 903-915. View this article in WRRO
• Wailoo A, Hock ES, Stevenson M, Martyn-St James M, Rawdin A, Simpson E, Wong R, Dracup N, Scott DL & Young A (2017) The clinical effectiveness and Cost-Effectiveness of Treat-To-Target strategies in rheumatoid arthritis: A systematic review and cost-effectiveness analysis. Health Technology Assessment, 21(71), 1-258. View this article in WRRO
• Bermejo I, Stevenson M, Archer R, Stevens JW, Goka E, Clowes M, Scott DL & Young A (2017) Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 35(11), 1141-1151. View this article in WRRO
• Ren S, Minton J, Whyte S, Latimer N & Stevenson M (2017) A New Approach for Sampling Ordered Parameters in Probabilistic Sensitivity Analysis. PharmacoEconomics. View this article in WRRO
• Möller J, Davis S, Stevenson M & Caro JJ (2017) Validation of a DICE Simulation Against a Discrete Event Simulation Implemented Entirely in Code. PharmacoEconomics, 35(10), 1103-1109. View this article in WRRO
• Bermejo I, Stevenson M, Cooper K, Harnan S, Hamilton J, Clowes M, Carroll C, Harrison T & Saha S (2017) Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. View this article in WRRO
• Stevenson MD, Wailoo AJ, Tosh JC, Hernandez-Alava M, Gibson LA, Stevens JW, Archer RJ, Simpson EL, Hock ES, Young A & Scott DL (2017) The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate. Journal of Rheumatology, 44(7), 973-980. View this article in WRRO
• Scott DL & Stevenson MD (2017) Treating active rheumatoid arthritis with Janus kinase inhibitors. Lancet. View this article in WRRO
• Thomas KH, Caldwell D, Dalili MN, Gunnell D, Munafò MR, Stevenson M & Welton NJ (2017) How do smoking cessation medicines compare with respect to their neuropsychiatric safety? A protocol for a systematic review, network meta-analysis and cost-effectiveness analysis.. BMJ Open, 7(6), e015414-e015414. View this article in WRRO
• Mason S, Kuczawski M, Teare MD, Stevenson M, Goodacre S, Ramlakhan S, Morris F & Rothwell J (2017) AHEAD Study: an observational study of the management of anticoagulated patients who suffer head injury. BMJ Open, 7(1). View this article in WRRO
• Fuller GW, Hernandez M, Pallott D, Lecky F, Stevenson M & Gabbe B (2017) Health State Preference Weights for the Glasgow Outcome Scale Following Traumatic Brain Injury: A Systematic Review and Mapping Study. Value in Health, 20(1), 141-151. View this article in WRRO
• Kuczawski ML, Stevenson M, Goodacre S, Teare MD, Ramlakhan S, Morris F & Mason S (2016) Should all anticoagulated patients with head injury receive a CT scan? Decision-analysis modelling of an observational cohort. BMJ Open. View this article in WRRO
• Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, Hernandez-Alava M, Paisley S, Dickinson K, Scott D , Young A et al (2016) Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technology Assessment, 20(35), 611-614.
• Kearns B, Pandor A, Stevenson M, Hamilton J, Chambers D, Clowes M, Graham J & Kumar MS (2016) Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 35(4), 415-424. View this article in WRRO
• Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M , Strong M et al (2016) A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technology Assessment, 20(78), 1-406. View this article in WRRO
• Rafia R, Scope A, Harnan S, Stevens JW, Stevenson M & Lobo A (2016) Vedolizumab for Treating Moderately to Severely Active Crohn’s Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 34(12), 1241-1253. View this article in WRRO
• Squires H, Stevenson M, Simpson E, Harvey R & Stevens J (2016) Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 34(7), 673-680. View this article in WRRO
• Stevenson M, Pandor A, Martyn-St James M, Rafia R, Uttley L, Stevens J, Sanderson J, Wong R, Perkins GD, McMullan R & Dark P (2016) Sepsis: the LightCycler SeptiFast Test MGRADE®, SepsiTest™ and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi - a systematic review and economic evaluation.. Health Technology Assessment, 20(46), 1-246. View this article in WRRO
• Morrell CJ, Sutcliffe P, Booth A, Stevens J, Scope A, Stevenson M, Harvey R, Bessey A, Cantrell A, Dennis C-L , Ren S et al (2016) A systematic review, evidence synthesis and meta-analysis of quantitative and qualitative studies evaluating the clinical effectiveness, the cost-effectiveness, safety and acceptability of interventions to prevent postnatal depression. Health Technology Assessment, 20(37), 1-414. View this article in WRRO
• Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, Hernandez-Alava M, Paisley S, Dickinson K, Scott D , Young A et al (2016) Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technology Assessment, 20(35), 1-610. View this article in WRRO
• Pandor A, Pollard D, Chico T, Henderson R & Stevenson M (2016) Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 34(5), 463-477. View this article in WRRO
• Uttley L, Stevenson M, Scope A, Rawdin A & Sutton A (2015) The clinical and cost effectiveness of group art therapy for people with non-psychotic mental health disorders: a systematic review and cost-effectiveness analysis. BMC Psychiatry, 15. View this article in WRRO
• Stevenson M, Pandor A, Stevens JW, Rawdin A, Rice P, Thompson J & Morgan MY (2015) Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 33(8), 833-847. View this article in WRRO
• Uttley L, Stevenson M, Scope A, Rawdin A & Sutton A (2015) Erratum to: The clinical and cost effectiveness of group art therapy for people with non-psychotic mental health disorders: a systematic review and cost-effectiveness analysis. BMC Psychiatry, 15(1). View this article in WRRO
• Knott A, Stevenson M & Harlow SKM (2015) Benchmarking rehabilitation practice in the intensive care unit. Journal of the Intensive Care Society, 16(1), 24-30.
• Tosh J, Stevenson M & Akehurst R (2014) Health Economic Modelling of Treatment Sequences for Rheumatoid Arthritis: A Systematic Review. Current Rheumatology Reports, 16(10). View this article in WRRO
• Stevenson MD & Selby PL (2014) Erratum to: Modelling the Cost Effectiveness of Interventions for Osteoporosis: Issues to Consider. PharmacoEconomics, 32(10), 1029-1029. View this article in WRRO
• Leaviss J, Hummel S, Carroll C, Ren S, Stevens JW, Everson-Hock E, Cantrell A, Stevenson M & Michaels J (2014) Clinical and cost-effectiveness of minimally invasive techniques for the treatment of varicosis: Systematic review and economic evaluation. Vasomed, 26(4), 210-211.
• Stevenson MD & Selby PL (2014) Modelling the cost effectiveness of interventions for osteoporosis: issues to consider.. Pharmacoeconomics, 32(8), 735-743. View this article in WRRO
• Stevenson M, Tappenden P & Squires H (2014) Methods for handling uncertainty within pharmaceutical funding decisions. International Journal of Systems Science, 45(1), 60-68. View this article in WRRO
• Leaviss J, Sullivan W, Ren S, Everson-Hock E, Stevenson M, Stevens JW, Strong M & Cantrell A (2014) What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation.. Health Technol Assess, 18(33), 1-120.
• Simpson EL, Kearns B, Stevenson MD, Cantrell AJ, Littlewood C & Michaels JA (2014) Enhancements to angioplasty for peripheral arterial occlusive disease: systematic review, cost-effectiveness assessment and expected value of information analysis.. Health Technol Assess, 18(10), 1-252.
• Holmes M, Rathbone J, Littlewood C, Rawdin A, Stevenson M, Stevens J, Archer R, Evans P & Wang J (2014) Routine echocardiography in the management of stroke and transient ischaemic attack: a systematic review and economic evaluation.. Health Technol Assess, 18(16), 1-176.
• Stevenson M, Gomersall T, Lloyd Jones M, Rawdin A, Hernández M, Dias S, Wilson D & Rees A (2014) Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for the treatment of osteoporotic vertebral fractures: a systematic review and cost-effectiveness analysis.. Health Technol Assess, 18(17), 1-290.
• Uttley L, Kearns B, Ren S & Stevenson M (2013) Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar I disorder in children and adolescents: a NICE single technology appraisal.. Pharmacoeconomics, 31(11), 981-990.
• McKenna C, Maund E, Sarowar M, Fox D, Stevenson M, Pepper C, Woolacott N & Palmer S (2013) Dronedarone for the treatment of atrial fibrillation. A NICE single technology appraisal. PharmacoEconomics - Italian Research Articles, 15(2), 91-100.
• Carroll C, Hummel S, Leaviss J, Ren S, Stevens JW, Everson-Hock E, Cantrell A, Stevenson M & Michaels J (2013) Clinical effectiveness and cost-effectiveness of minimally invasive techniques to manage varicose veins: a systematic review and economic evaluation.. Health Technol Assess, 17(48), i-141.
• Holmes MW, Goodacre S, Stevenson MD, Pandor A & Pickering A (2013) The cost-effectiveness of diagnostic management strategies for children with minor head injury.. Arch Dis Child, 98(12), 939-944.
• Kearns BC, Michaels JA, Stevenson MD & Thomas SM (2013) Cost-effectiveness analysis of enhancements to angioplasty for infrainguinal arterial disease. British Journal of Surgery, 100(9), 1180-1188.
• Simpson E, Stevenson M, Scope A, Poku E, Minton J & Evans P (2013) Echocardiography in newly diagnosed atrial fibrillation patients: a systematic review and economic evaluation.. Health Technol Assess, 17(36), 1-vi.
• Kearns B, Lloyd Jones M, Stevenson M & Littlewood C (2013) Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal.. Pharmacoeconomics, 31(6), 479-488.
• Tosh J, Archer R, Davis S, Stevenson M & Stevens JW (2013) Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs: a NICE single technology appraisal.. Pharmacoeconomics, 31(8), 653-661.
• Rafia R, Simpson E, Stevenson M & Papaioannou D (2013) Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal.. Pharmacoeconomics, 31(6), 471-478.
• Whyte S, Pandor A & Stevenson M (2012) Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal.. Pharmacoeconomics, 30(12), 1119-1132.
• Hummel SR, Stevenson MD, Simpson EL & Staffurth J (2012) A Model of the Cost-effectiveness of Intensity-modulated Radiotherapy in Comparison with Three-dimensional Conformal Radiotherapy for the Treatment of Localised Prostate Cancer. Clinical Oncology, 24(10).
• Papaioannou D, Rafia R, Rathbone J, Stevenson M, Buckley Woods H & Stevens J (2012) Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.. Health Technol Assess, 16(37), 1-iv.
• Thokala P, Goodacre SW, Collinson PO, Stevens JW, Mills NL, Newby DE, Morris F, Kendall J & Stevenson MD (2012) Cost-effectiveness of presentation versus delayed troponin testing for acute myocardial infarction. Heart, 98(20), 1498-1503.
• Ara R, Blake L, Gray L, Hernández M, Crowther M, Dunkley A, Warren F, Jackson R, Rees A, Stevenson M , Abrams K et al (2012) What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.. Health Technol Assess, 16(5), iii-195.
• Bates SM, Jaeschke R, Stevens SM, Goodacre S, Wells PS, Stevenson MD, Kearon C, Schunemann HJ, Crowther M, Pauker SG , Makdissi R et al (2012) Diagnosis of DVT: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 141(2 SUPPL.), e351S-e418S.
• Stevenson M, Lloyd-Jones M, Morgan MY & Wong R (2012) Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.. Health technology assessment (Winchester, England), 16(4), 1-174.
• Stevenson M & Pandor A (2012) Febuxostat for the treatment of hyperuricemia in patients with gout: The National Institute for Health and Clinical Excellence single technology appraisal process. PharmacoEconomics - Italian Research Articles, 14(1), 47-54.
• McKenna C, Maund E, Sarowar M, Fox D, Stevenson M, Pepper C, Woolacott N & Palmer S (2012) Dronedarone for the treatment of atrial fibrillation: A NICE single technology appraisal. PharmacoEconomics, 30(1), 35-46.
• Holmes MW, Goodacre S, Stevenson MD, Pandor A & Pickering A (2012) The cost-effectiveness of diagnostic management strategies for adults with minor head injury.. Injury, 43(9), 1423-1431.
• Ara R, Pandor A, Stevens J, Rafia R, Ward SE, Rees A, Durrington PN, Reynolds TM, Wierzbicki AS & Stevenson M (2012) Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?. Eur J Prev Cardiol, 19(3), 474-483.
• Carroll C, Stevenson M, Scope A, Evans P & Buckley S (2011) Hemiarthroplasty and total hip arthroplasty for treating primary intracapsular fracture of the hip: a systematic review and cost-effectiveness analysis.. Health technology assessment (Winchester, England), 15(36), 1-74.
• Madan J, Stevenson MD, Cooper KL, Ades AE, Whyte S & Akehurst R (2011) Consistency between direct and indirect trial evidence: is direct evidence always more reliable?. Value Health, 14(6), 953-960. View this article in WRRO
• Holmes MW, Goodacre S, Stevenson MD, Pandor A & Pickering A (2011) The cost-effectiveness of diagnostic management strategies for adults with minor head injury. Injury.
• Pandor A, Goodacre S, Harnan S, Holmes M, Pickering A, Fitzgerald P, Rees A & Stevenson M (2011) Diagnostic management strategies for adults and children with minor head injury: a systematic review and an economic evaluation.. Health Technol Assess, 15(27), 1-202.
• Whyte S, Cooper KL, Stevenson MD, Madan J & Akehurst R (2011) Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom.. Value Health, 14(4), 465-474.
• Papaioannou D, Rafia R, Stevenson MD, Stevens JW & Evans P (2011) Trabectedin for the treatment of relapsed ovarian cancer.. Health Technol Assess, 15 Suppl 1, 69-75.
• Carroll C, Stevenson M, Scope A, Evans P & Buckley S (2011) Hemiarthroplasty and total hip arthroplasty for treating primary intracapsular fracture of the hip: a systematic review and cost-effectiveness analysis.. Health Technol Assess, 15(36), 1-74.
• Cooper KL, Madan J, Whyte S, Stevenson MD & Akehurst RL (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: Systematic review and meta-analysis. BMC Cancer, 11. View this article in WRRO
• Hummel S, Simpson EL, Hemingway P, Stevenson MD & Rees A (2011) Intensity-modulated radiotherapy for the treatment of prostate cancer: A systematic review and economic evaluation. Journal of Urology, 186(2), 534-535.
• Stevenson M & Pandor A (2011) Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal.. Pharmacoeconomics, 29(2), 133-140.
• Stevenson MD & Jones ML (2011) The cost effectiveness of a randomized controlled trial to establish the relative efficacy of vitamin K1 compared with alendronate.. Med Decis Making, 31(1), 43-52.
• Whyte S, Pandor A, Stevenson M & Rees A (2010) Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.. Health technology assessment (Winchester, England), 14(Suppl. 2), 47-53. View this article in WRRO
• Hummel S, Simpson EL, Hemingway P, Stevenson MD & Rees A (2010) Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation.. Health Technol Assess, 14(47), 1-iv.
• Stevenson MD, Scope A, Sutcliffe PA, Booth A, Slade P, Parry G, Saxon D, Kalthenthaler E & group cognitive behavioural therapy for postnatal depression advisory group (2010) Group cognitive behavioural therapy for postnatal depression: a systematic review of clinical effectiveness, cost-effectiveness and value of information analyses.. Health Technol Assess, 14(44), 1-iv.
• Owen J, Carroll C, Cooke J, Formby E, Hayter M, Hirst J, Lloyd Jones M, Stapleton H, Stevenson M & Sutton A (2010) School-linked sexual health services for young people (SSHYP): a survey and systematic review concerning current models, effectiveness, cost-effectiveness and research opportunities.. Health Technol Assess, 14(30), 1-iv.
• Simpson EL, Rafia R, Stevenson MD & Papaioannou D (2010) Trabectedin for the treatment of advanced metastatic soft tissue sarcoma.. Health Technol Assess, 14 Suppl 1, 63-67.
• Stevenson MD, Scope A & Sutcliffe PA (2010) The cost-effectiveness of group cognitive behavioral therapy compared with routine primary care for women with postnatal depression in the UK.. Value Health, 13(5), 580-584.
• Stevenson MD, Simpson EL, Rawdin AC & Papaioannou DE (2010) A review of discrete event simulation in National Coordinating Centre for Health Technology Assessment-funded work and a case study exploring the cost-effectiveness of testing for thrombophilia in patients presenting with an initial idiopathic venous thromboembolism.. J. Simulation, 4, 14-23.
• Maund E, McKenna C, Sarowar M, Fox D, Stevenson M, Pepper C, Palmer S & Woolacott N (2010) Dronedarone for the treatment of atrial fibrillation and atrial flutter.. Health technology assessment (Winchester, England), 14(Suppl. 2), 55-62.
• Madan J, Rawdin A, Stevenson M & Tappenden P (2010) A rapid-response economic evaluation of the UK NHS Cancer Reform Strategy breast cancer screening program extension via a plausible bounds approach.. Value Health, 13(2), 215-221.
• Wardlaw JM, Stevenson MD, Chappell F, Rothwell PM, Gillard J, Young G, Thomas SM, Roditi G & Gough MJ (2009) Carotid Artery Imaging for Secondary Stroke Prevention Both Imaging Modality and Rapid Access to Imaging Are Important. STROKE, 40(11), 3511-3517.
• Michaels JA, Campbell WB, King BM, Macintyre J, Palfreyman SJ, Shackley P & Stevenson MD (2009) A prospective randomised controlled trial and economic modelling of antimicrobial silver dressings versus non-adherent control dressings for venous leg ulcers: the VULCAN trial.. Health Technol Assess, 13(56), 1-iii.
• Stevenson MD, Oakley JE, Lloyd Jones M, Brennan A, Compston JE, McCloskey EV & Selby PL (2009) The cost-effectiveness of an RCT to establish whether 5 or 10 years of bisphosphonate treatment is the better duration for women with a prior fracture.. Med Decis Making, 29(6), 678-689. View this article in WRRO
• Pandor A, Fitzgerald P, Stevenson M & Papaioannou D (2009) Mifamurtide for the treatment of osteosarcoma: a single technology appraisal. HEALTH TECHNOL ASSES, 13, 55-60.
• Stevenson M & Pandor A (2009) Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal. HEALTH TECHNOL ASSES, 13, 37-42.
• Stevenson M, Scope A, Holmes M, Rees A & Kaltenthaler E (2009) Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal. HEALTH TECHNOL ASSES, 13, 43-48.
• Michaels JA, Campbell B, King B, Palfreyman SJ, Shackley P & Stevenson M (2009) Randomized controlled trial and cost-effectiveness analysis of silver-donating antimicrobial dressings for venous leg ulcers (VULCAN trial).. Br J Surg, 96(10), 1147-1156.
• Stevenson M, Lloyd-Jones M & Papaioannou D (2009) Vitamin K to prevent fractures in older women: systematic review and economic evaluation.. Health technology assessment (Winchester, England), 13(45).
• Stevenson M, Lloyd-Jones M & Papaioannou D (2009) Vitamin K to prevent fractures in older women: systematic review and economic evaluation.. Health Technol Assess, 13(45), iii-134.
• Stevenson MD, Macdonald FC, Langley J, Hunsche E & Akehurst R (2009) The cost-effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III.. Value Health, 12(8), 1100-1105.
• Stevenson MD, Oakley JE, Chick SE & Chalkidou K (2009) The cost-effectiveness of surgical instrument management policies to reduce the risk of vCJD transmission to humans. J OPER RES SOC, 60(4), 506-518. View this article in WRRO
• Michaels JA, King B, MacIntyre JB, Palfreyman SJ, Shackley PM, Stevenson MD & Campbell WB (2009) Randomised controlled trial of anti-microbial agents for the treatment of venous leg ulcers. British Journal of Surgery, 96(S1), 15-15.
• Simpson EL, Stevenson MD, Rawdin A & Papaioannou D (2009) Thrombophilia testing in people with venous thromboembolism: systematic review and cost-effectiveness analysis.. Health Technol Assess, 13(2), iii-91.
• Sutton AJ, Cooper NJ, Goodacre S & Stevenson M (2008) Integration of meta-analysis and economic decision modeling for evaluating diagnostic tests. MED DECIS MAKING, 28(5), 650-667.
• Stevenson M (2008) The population of health economic models is critical. Bone, 43(1), 214-214.
• Ding HS, Koinuma N, Stevenson M, Ito M & Monma Y (2008) The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis. J BONE MINER METAB, 26(1), 34-41.
• O'Hagan A, Stevenson M & Madan J (2007) Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA.. Health Econ, 16(10), 1009-1023.
• Kanis JA, Stevenson M, McCloskey EV, Davis S & Lloyd-Jones M (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.. Health technology assessment (Winchester, England), 11(7).
• Stevenson M, Davis S, Lloyd-Jones M & Beverley C (2007) The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women.. Health Technol Assess, 11(4), 1-134.
• Kanis JA, Stevenson M, McCloskey EV, Davis S & Lloyd-Jones M (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. HEALTH TECHNOL ASSES, 11(7), 1-+.
• Goodacre S, Stevenson M, Wailoo A, Sampson F, Sutton AJ & Thomas S (2006) Optimal algorithm for evaluating suspected DVT. Journal of Family Practice, 55(9), 754.
• Wardlaw JM, Chappell FM, Stevenson M, De Nigris E, Thomas S, Gillard J, Berry E, Young G, Rothwell P, Roditi G , Gough M et al (2006) Accurate, practical and cost-effective assessment of carotid stenosis in the UK. HEALTH TECHNOL ASSES, 10(30), 1-+.
• Goodacre S, Stevenson M, Wailoo A, Sampson F, Sutton AJ & Thomas S (2006) How should we diagnose suspected deep-vein thrombosis?. QJM, 99(6), 377-388.
• Goodacre S, Sampson F, Stevenson M, Wailoo A, Sutton A, Thomas S, Locker T & Ryan A (2006) Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis.. Health technology assessment (Winchester, England), 10(15).
• Goodacre S, Sampson F, Stevenson M, Wailoo A, Sutton A, Thomas S, Locker T & Ryan A (2006) Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis. Health Technology Assessment, 10(15). View this article in WRRO
• Stevenson M, Davis S & Kanis J (2006) The hospitalisation costs and out-patient costs of fragility fractures. Women's Health Medicine, 3(4), 149-151.
• Stevenson MD, Brazier JE, Calvert NW, Lloyd-Jones M, Oakley JE & Kanis JA (2005) Description of an individual patient methodology for calculating the cost-effectiveness of treatments for osteoporosis in women. J OPER RES SOC, 56(2), 214-221.
• Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S & Oakley J (2005) A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.. Health Technol Assess, 9(22), 1-160. View this article in WRRO
• Stevenson MD, Oakley J & Chilcott JB (2004) Gaussian process modeling in conjunction with individual patient simulation modeling: a case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis.. Med Decis Making, 24(1), 89-100.
• Stevenson M, Beard S, Finn A & Brennan A (2002) Estimating the potential health gain and cost consequences of introducing a pre-school DTPa pertussis booster into the UK child vaccination schedule.. Vaccine, 20(13-14), 1778-1786.
• Kanis JA, Brazier JE, Stevenson M, Calvert NW & Lloyd Jones M (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis.. Health technology assessment (Winchester, England), 6(29), 1-146.
• Peters J, Stevenson M, Beverley C, Lim JN & Smith S (2002) The clinical effectiveness and cost-effectiveness of inhaler devices used in the routine management of chronic asthma in older children: a systematic review and economic evaluation.. Health technology assessment (Winchester, England), 6(5). View this article in WRRO
• Kanis JA, Brazier JE, Stevenson M, Calvert NW & Lloyd Jones M (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis.. Health Technol Assess, 6(29), 1-146.
• Stevenson MD, Oakley PA, Beard SM, Brennan A & Cook AL (2001) Triaging patients with serious head injury: results of a simulation evaluating strategies to bypass hospitals without neurosurgical facilities.. Injury, 32(4), 267-274.
• Harnan S, Hamilton J, Simpson E, Clowes M, Navega Biz A, Whyte S, Ren S, Cooper K, Abulafi M, Ball A , Beton S et al () Faecal Immunochemical Tests For Patients With Symptoms Suggestive Of Colorectal Cancer: An Updated Systematic Review And Multiple-Threshold Meta-Analysis of Diagnostic Test Accuracy Studies. Colorectal Disease.
• Goodacre S, Sutton L, Ennis K, Thomas B, Hawksworth O, Iftikhar K, Croft SJ, Fuller G, Waterhouse S, Hind D , Stevenson M et al () Prehospital early warning scores for adults with suspected sepsis: the PHEWS observational cohort and decision-analytic modelling study. Health Technology Assessment, 1-93.
• Bullement A, Stevenson MD, Baio G, Shields GE & Latimer NR () A systematic review of methods to incorporate external evidence into trial-based survival extrapolations for health technology assessment. Medical Decision Making.
• Dark P, Perkins GD, McMullan R, McAuley D, Gordon AC, Clayton J, Mistry D, Young K, Regan S, McGowan N , Stevenson M et al () biomArker-guided Duration of Antibiotic treatment in hospitalised Patients with suspecTed Sepsis (ADAPT-Sepsis): A protocol for a multicentre randomised controlled trial. Journal of the Intensive Care Society, 175114372311691-175114372311691.
• Kearns B, Stevenson MD, Triantafyllopoulos K & Manca A () Dynamic and Flexible Survival Models for Extrapolation of Relative Survival: A Case Study and Simulation Study. Medical Decision Making, 0272989X2211076-0272989X2211076.
• Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M , Strong M et al () Corrigendum: A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technology Assessment, 20(78), 407-424. View this article in WRRO
• Papaioannou D, Rafia R, Stevenson MD, Stevens JW & Evans P () Trabectedin for the treatment of relapsed ovarian cancer. Health Technology Assessment, 15(Suppl 1), 69-75.
• Whyte S, Pandor A, Stevenson M & Rees A () Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer. Health Technology Assessment, 14(Suppl 2), 47-53.
• Simpson EL, Rafia R, Stevenson MD & Papaioannou D () Trabectedin for the treatment of advanced metastatic soft tissue sarcoma. Health Technology Assessment, 14(Suppl 1), 63-67.
• Stevenson M, Scope A, Holmes M, Rees A & Kaltenthaler E () Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal. Health Technology Assessment, 13(Suppl 3), 43-48.
• Stevenson M & Pandor A () Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal. Health Technology Assessment, 13(Suppl 3), 37-42.
• Hock ES, Martyn-St James M, Wailoo A, Scott DL, Stevenson M, Rawdin A, Simpson EL, Dracup N & Young A () Treat-to-Target Strategies in Rheumatoid Arthritis: a Systematic Review and Cost-Effectiveness Analysis. SN Comprehensive Clinical Medicine.
• Lecky F, Russell W, Fuller G, McClelland G, Pennington E, Goodacre S, Han K, Curran A, Holliman D, Freeman J , Chapman N et al () The Head Injury Transportation Straight to Neurosurgery (HITS-NS) randomised trial: a feasibility study. Health Technology Assessment, 20(1), 1-198. View this article in WRRO
• Uttley L, Scope A, Stevenson M, Rawdin A, Taylor Buck E, Sutton A, Stevens J, Kaltenthaler E, Dent-Brown K & Wood C () Systematic review and economic modelling of the clinical effectiveness and cost-effectiveness of art therapy among people with non-psychotic mental health disorders. Health Technology Assessment, 19(18), 1-120. View this article in WRRO

Chapters

• Peters J & Stevenson M (2005) Modelling the health cost of cold damp housing, Cutting the Cost of Cold: Affordable Warmth for Healthier Homes (pp. 143-152).

Conference proceedings papers

• Singh J, Stevenson M, Hyrich K, Gillies C, Abrams K & Bujkiewicz S (2024) Use Of Real-World Data In Cost-effectiveness Analysis Of Sequential Biologic Treatment For Rheumatoid Arthritis. MEDICAL DECISION MAKING, Vol. 44(2) (pp NP49-NP50)
• Singh J, Stevenson MD, Hyrich K, Gillies C, Abrams K & Bujkiewicz S (2022) USE OF REAL-WORLD DATA IN COST-EFFECTIVENESS ANALYSIS OF SEQUENTIAL BIOLOGIC TREATMENT FOR RHEUMATOID ARTHRITIS. VALUE IN HEALTH, Vol. 25(12) (pp S373-S374)
• Li NN, Sawyer EK, Maruszczyk K, Slomka M, Burke T, Martin AP, Stevenson M, Guzauskas G & O'Hara J (2020) The economic burden of hemophilia B - a lifetime decision analytic model. HAEMOPHILIA, Vol. 26 (pp 111-111)
• Li NN, Sawyer EK, Maruszczyk K, Slomka M, Burke T, Martin AP, O'Hara J & Stevenson M (2020) GENE THERAPY FOR PEOPLE WITH HAEMOPHILIA B (PWHB): DEVELOPMENT OF A COST-EFFECTIVENESS MODEL FRAMEWORK. HAEMOPHILIA, Vol. 26 (pp 107-107)
• Hawes C, Camp C, Burke T, O'Hara J, Stevenson MD, Lomax H, Trueman D & Jain M (2020) COMPARING THE SENSITIVITY OF PATIENT-LEVEL DISCRETE EVENT SIMULATION AND COHORT HEALTH-STATE TRANSITION MODELLING FRAMEWORKS IN THE ADVENT OF NOVEL THERAPIES FOR PEOPLE WITH SEVERE HAEMOPHILIA A. HAEMOPHILIA, Vol. 26 (pp 65-66)
• Kearns BC, Stevenson M, Triantafyllopoulos K & Manca A (2019) PNS327: Do flexible survival models provide better extrapolations than standard survival models? A simulation study. Value in Health, Vol. 22(Supplement 3) (pp S819-S819). Copenhagen, Denmark, 2 November 2019 - 2 November 2019. View this article in WRRO
• Kearns BC, Stevenson M, Triantafyllopoulos K & Manca A (2019) PCN444: Dynamic survival models for incorporating external evidence when extrapolating overall survival: a case study. Value in Health, Vol. 22(S3) (pp S522-S522). Copenhagen, Denmark, 2 November 2019 - 2 November 2019. View this article in WRRO
• Srivastava T, Strong M, Stevenson MD & Dodd P (2019) PNS337: Improving on cycle corrections for time-homogeneous markov models. Value in Health, Vol. 22(Suppl 3) (pp S821-S821). Copenhagen, Denmark, 2 November 2019 - 2 November 2019. View this article in WRRO
• Thokala P, Stevenson M, Kumar VM, Ren S, Chapman R, Ellis A & Rind D (2019) PRO15 COST-EFFECTIVENESS OF NUSINERSEN AND ONASEMNOGENE ABEPARVOVEC FOR INFANTILE-ONSET SPINAL MUSCULAR ATROPHY (TYPE I SMA) IN THE US. Value in Health, Vol. 22 (pp S337-S338)
• O'Hara J, Burke T, Chowdary P, Khair K, Laffan M, McLaughlin P, Pasi J, Stevenson M, Willan J, Hawes C , Jain M et al (2019) Key findings from an expert validation workshop to establish an appropriate modelling framework in severe haemophilia A. HAEMOPHILIA, Vol. 25 (pp 182-183) View this article in WRRO
• O'Hara J, Jain M, Stevenson M, Burke T & Camp C (2019) Using patient-level simulation to model patient-centric outcomes in the advent of gene therapy in severe haemophilia A. HAEMOPHILIA, Vol. 25 (pp 66-67) View this article in WRRO
• Pollard D, Goodacre S, Stevenson M & Fuller G (2017) 10 Decision analysis modelling of diagnostic strategies for suspected pulmonary embolism in pregnancy: the DiPEP economic evaluation. Emergency Medicine Journal, Vol. 34(12) (pp A867-A868)
• Hatswell AJ, Bullement A, Paulden M & Stevenson M (2017) Probabilistic Sensitivity Analysis In Health Economic Models; How Many Simulations Should We Run?. Value in Health, Vol. 20(9) (pp A746-A746)
• Doherty M, Jenkins W, Richardson H, Abhishek A, Ashton D, Barclay C, Duley L, Jones H, Santarelli M, Sarmanova A , Stevenson M et al (2017) OP0268 Nurse-led care versus general practitioner care of people with gout: a uk community-based randomised controlled trial. Oral Presentations
• Romero CP, Stevenson MD & Dixon S (2017) THE CLINICAL AND COST-EFFECTIVENESS OF DIFFERENT MATERNAL SYPHILIS SCREENING STRATEGIES IN BRAZIL. VALUE IN HEALTH, Vol. 20(9) (pp A572-A572)
• Wlodarczyk J, Hunsche E, Silberberg B, Kemp D, Anell B, Corcoran K, Minacori R, Stevenson M & Beaudet A (2016) COST-EFFECTIVENESS ANALYSIS OF SELEXIPAG VERSUS INHALED ILOPROST IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) IN SWEDEN. VALUE IN HEALTH, Vol. 19(7) (pp A556-A556), 29 October 2016 - 2 November 2016. View this article in WRRO
• Morrell J, Sutcliffe P, Stevenson M, Stevens J, Booth A, Scope A, Bessey A, Dennis C-L, Cantrell A, Barkham M , Churchill D et al (2015) Prevention of postnatal depression: a meta-analysis of interventions to prevent postnatal depression. Journal of Reproductive and Infant Psychology, Vol. 33(3) (pp E3-E4), 13 September 2016 - 14 September 2016. View this article in WRRO
• Tosh J, Stevenson M, Akehurst R & Strong M (2015) Simulation optimisation of Treatment Sequences for Rheumatoid arthritis. Value in Health, Vol. 18(7) (pp A343-A343)
• Stevenson M, Rawdin A, Uttley L & Sutton A (2014) The Cost Effectiveness of Group Art Therapy for Patients with Non-Psychotic Mental Health Disorders in England And Wales. Value in Health, Vol. 17(7) (pp A458-A459)
• Tosh J, Stevenson M, Strong M & Akehurst R (2014) A Framework for the Economic Evaluation of Sequential Therapies for Chronic Conditions. Value in Health, Vol. 17(7) (pp A584-A584)
• Kuczawski M, Mason S, Stevenson M, Holmes M, Teare MD, Ramlakhan S, Goodacre S, Morris F & Harper R (2014) ADHERENCE TO THE NICE HEAD INJURY GUIDELINES 2007 AND 2014 IN ANTICOAGULATED PATIENTS. Emergency Medicine Journal, Vol. 31(9) (pp 775.2-775)
• Mason S, Kuczawski M, Teare MD, Stevenson M, Holmes M, Ramlakhan S, Goodacre S, Morris F & Harper R (2014) THE AHEAD STUDY: MANAGING ANTICOAGULATED PATIENTS WHO SUFFER HEAD INJURY. Emergency Medicine Journal, Vol. 31(9) (pp 775.1-775)
• Wailoo AJ, Stevenson M, Tosh J, Hernández M, Stevens JW, Archer R, Simpson E, everson HE, Scott D, Young A , Paisley S et al (2014) The Cost-Effectiveness of Biologic Dmards in Patients With Severe or Mild-To-Severe Rheumatoid Arthritis After Conventional Dmards. Value in Health, Vol. 17(7) (pp A380-A380)
• Uttley L, Kearns B & Stevenson M (2013) SHOULD THERE BE AN OPTION TO "UNREFER" NICE SINGLE TECHNOLOGY APPRAISALS: CASE STUDY OF ARIPIPRAZOLE FOR BIPOLAR I DISORDER IN ADOLESCENTS. VALUE IN HEALTH, Vol. 16(7) (pp A615-A616)
• Chrosny W, Stevenson M & Munzer A (2013) COMPARISON OF MARKOV AND DISCRETE EVENT SIMULATION MODELING TECHNIQUES WITH APPLICATION TO COST EFFECTIVENESS ANALYSES. VALUE IN HEALTH, Vol. 16(7) (pp A587-A587)
• Tosh J, Stevenson M & Akehurst R (2013) HEALTH ECONOMIC MODELLING OF SEQUENTIAL THERAPIES FOR RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW. VALUE IN HEALTH, Vol. 16(7) (pp A565-A565)
• Morgan MY, Stevenson MD & Jones ML (2012) THE CLINICAL UTILITY AND COST-EFFECTIVENESS OF NON-INVASIVE TESTS FOR DETECTING FIBROSIS IN PATIENTS WITH SUSPECTED ALCOHOL-RELATED LIVER DISEASE. GUT, Vol. 61 (pp A203-A203)
• Perkins J, Zhou Z, Stevenson M, Mahan G, Mashford B, Niu Y, Breen C, Hamilton C, Steckel JS, Ritter J , Bulovic V et al (2011) Full-color active-matrix quantum dot light emitting device displays. Proceedings of the International Display Workshops, Vol. 2 (pp 1181-1184)
• Vargas-Palacios A, Stevenson M, Duenas A & Wailloo A (2011) COMPARING THE USE OF DYNAMIC AND STATIC INFECTIOUS DISEASE MODELS IN LATIN AMERICA WITH NORTH AMERICA, EUROPE, ASIA AND OTHER REGIONS.. VALUE IN HEALTH, Vol. 14(7) (pp A541-A541)
• Rafia R, Papaioannou D, Stevenson M, Rathbone J & Woods HB (2011) EVALUATING THE COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO CHEMOTHERAPY IN THE FIRST LINE TREATMENT OF FOLLICULAR LYMPHOMA PATIENTS IN THE UK. VALUE IN HEALTH, Vol. 14(7) (pp A445-A445)
• Soini EJ, Stevenson MD, Martikainen JA & Akehurst RL (2009) COST-UTILITY OF BOSENTAN IN THE FIRST-LINE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN FINLAND-A DISCRETE EVENT SIMULATION MODELLING. VALUE HEALTH, Vol. 12(7) (pp A335-A335)
• Stevenson MD, Macdonald FC, Langley J & Akehurst RL (2008) Cost-effectiveness of bosentan versus epoprostenol and no active treatment when added to palliative care for UK patients with pulmonary arterial hypertension of WHO functional class III. EUROPEAN HEART JOURNAL, Vol. 29 (pp 859-859)
• Stevenson MD, Rawdin AC, Karnon JD & Brennan A (2008) Clopidogrel is cost-effective compared with aspirin in United Kingdom patients with a myocardial infarction who subsequently sustain an ischaemic stroke or peripheral arterial disease event. VALUE HEALTH, Vol. 11(3) (pp A194-A195)
• Stevenson MD, MacDonald FC, Langley J & Akehurst RL (2008) Bosentan is a cost-effective treatment for united kingdom patients with pulmonary arterial hypertension of WHO class III. VALUE HEALTH, Vol. 11(3) (pp A197-A197)
• Stevenson MD, Brazier JE, Calvert NW, Lloyd-Jones M, Oakley JE & Kanis JA (2004) The cost-effectiveness of calcium and vitamin D in women with low dietary calcium intake. OSTEOPOROSIS INTERNATIONAL, Vol. 15 (pp S39-S40)
• Stevenson MD, Brazier JE, Calvert NW, Lloyd-Jones M, Oakley JE & Kanis JA (2004) The cost-effectiveness of bisphosphonates, raloxifene and teriparatide in women with a prior fracture, low BMD and replete of calcium and vitamin D. OSTEOPOROSIS INTERNATIONAL, Vol. 15 (pp S39-S39)
• Allder SJ, Stevenson M, Doyle C, Pandor A, Rothwell P, Venables G & Thomas SM (2004) Should we treat TIA as a medical emergency?. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, Vol. 75(8) (pp 1217-1217)
• Stevenson MD, Brazier JE, Lloyd-Jones M, Calvert N, Oakley J & Kanis JA (2004) The cost-effectiveness of bisphosphonates, raloxifene and hormone replacement therapy in women with established osteoporosis and replete of calcium and vitamin D. OSTEOPOROSIS INTERNATIONAL, Vol. 15 (pp S111-S111)
• Stevenson MD, Lloyd-Jones M, Brazier JE, Calvert N, Oakley J & Kanis JA (2004) The cost-effectiveness of calcium and vitamin D supplementation in women with low dietary intake of these nutrients and at risk of osteoporosis. OSTEOPOROSIS INTERNATIONAL, Vol. 15 (pp S87-S88)
• Stevenson MD, Brazier JE, Kanis J & Lloyd-Jones M (2000) Cost-effectiveness of current treatments for established female osteoporosis. OSTEOPOROSIS INT, Vol. 11 (pp S11-S11)

Reports

• Michaels J & Stevenson M (2020) Explaining national differences in the mortality of Covid-19 : individual patient simulation model to investigate the effects of testing policy and other factors on apparent mortality View this article in WRRO

Posters

• Ghabri S, Simpson EL, Ren S, Hock E, Archer R, Binard A, Pers Y, Stevens JW, Herpin C & Stevenson M (2018) PMS4 - RHEUMATOID ARTHRITIS TREATED WITH SIX-MONTHS OF FIRST-LINE BIOLOGIC OR BIOSIMILAR THERAPY: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS.
• Archer R, Clowes M, Hamilton J, Pandor A, Stevenson MD, Stevens JW, Hock ES & Essat M (2018) Addressing challenges in the conduct of a systematic review of clinical prediction models in rheumatoid arthritis. 25th Cochrane Colloquium, Edingurgh.
• Hamilton J, Archer R, Stevens J, Stevenson M, Hock E, Clowes M, Essat M, Poku E & Pandor A (2018) Clinical prediction models for patients with early rheumatoid arthritis: A systematic review and evidence synthesis. MEMTAM (Methods for Evaluation of medical prediction Models, Test And Biomarkers), Utecht, The Nethe.
• Tosh J, Stevenson M, Akehurst R & Strong M A Framework for the Economic Evaluation of Sequential Therapies for Chronic Conditions (2014).
• Rafia R, Papaioannou D, Stevenson M, Rathbone J & Woods H Evaluating the cost-effectiveness of the addition of rituximab to chemotherapy in the first-line treatment of Follicular Lymphoma patients in the UK.
• Simpson E, Stevenson M, Hock E, Wong R, Wakefield RJ, Conaghan PG, Estrach C & Edwards C Ultrasound to Guide Treatment Decisions in Rheumatoid Arthritis.
• Stevenson M, Rawdin A & Uttley L Cost effectiveness of group art therapy for patients with non-psychotic mental health disorders in England and Wales (2014).
• Stevenson M, Jones ML & Morgan M The cost-effectiveness of non-invasive liver tests for the detection of liver fibrosis in patients with suspected alcohol-related liver disease.

Other

• Michaels JA, Campbell WB, King BM, Palfreyman SJ, Shackley P & Stevenson MD (2010) Randomized controlled trial and cost-effectiveness analysis of silver-donating antimicrobial dressings for venous leg ulcers (VULCAN trial) (Br J Surg 2009; 96: 1147-1156) Reply. BRIT J SURG, 97(3), 460-460.

Preprints

• Abhishek A, Grainge MJ, Card T, Williams HC, Taal MW, Aithal GP, Fox CP, Mallen CD, Stevenson MD, Nakafero G & Riley RD (2023) Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation, Cold Spring Harbor Laboratory.
• Abhishek A, Nakafero G, Grainge MJ, Card T, Taal MW, Aithal GP, Fox CP, Mallen CD, Stevenson MD & Riley RD (2023) Monitoring for 5-aminosalicylate toxicity: prognostic model development and validation, Cold Spring Harbor Laboratory.
• Kearns B, Stevenson MD, Triantafyllopoulos K & Manca A () Comparing Current and Emerging Practice Models For the Extrapolation of Survival Data: A Simulation Study and Case-Study, Research Square Platform LLC.
• Kainz B, Makropoulos A, Oppenheimer J, Deane C, Mischkewitz S, Al-Noor F, Rawdin AC, Stevenson MD, Mandegaran R, Heinrich MP & Curry N () Non-invasive Diagnosis of Deep Vein Thrombosis from Ultrasound with Machine Learning, Cold Spring Harbor Laboratory.
• Srivastava T, Strong M, Stevenson MD & Dodd PJ () Improving Cycle Corrections in Discrete Time Markov Models: A Gaussian Quadrature Approach. View this article in WRRO
• Kainz B, Makropoulos A, Oppenheimer J, Deane C, Mischkewitz S, Al-Noor F, Rawdin AC, Stevenson MD, Heinrich‬ MP & Curry N () Non-Invasive Diagnosis of Deep Vein Thrombosis From Ultrasound With Machine Learning.
• Doherty M, Jenkins W, Richardson H, Sarmanova A, Abhishek A, Ashton D, Barclay C, Doherty S, Duley L, Hatton R , Rees F et al () Nurse-Led versus Usual (General Practitioner-Led) Care of People with Gout: A UK Community-Based, Two Year, Randomised Controlled Trial.